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http://dxObjective: The study objective was to investigate the protective effect of penehyclidine hydrochloride on intes-
tinal barrier function integrity and its therapeutic potential on endotoxemia and systemic inflammatory response
in patients undergoing cardiopulmonary bypass.
Methods: Forty patients undergoing cardiac valve replacement with cardiopulmonary bypass were enrolled in
the study. All patients were randomly divided into the penehyclidine hydrochloride or control group (20 patients
in each group). Patients in the penehyclidine hydrochloride group received an intravenous injection of 0.05 mg/kg
penehyclidine hydrochloride 10 minutes before cardiopulmonary bypass, and those in the control group were
given the same volume of saline. Blood samples for blood glucose, lactic acid, intestinal fatty acid binding pro-
tein, D-lactate, serum endotoxin (lipopolysaccharide), interleukin-6, and interleukin-10measurements were col-
lected during the following time points: immediately after anesthesia induction (T0), 10 minutes after the release
of aortic-clamping (T1), immediately after weaning from cardiopulmonary bypass (T2), 2 hours postoperatively
(T3), 6 hours postoperatively (T4), and 18 hours postoperatively (T5).
Results: Blood glucose, lactic acid, intestinal fatty acid binding protein, D-lactate, lipopolysaccharide,
interleukin-6, and interleukin-10 were significantly increased at all postoperative time points. At specific post-
operative time points, blood glucose, lactic acid, intestinal fatty acid binding protein, D-lactate, lipopolysaccha-
ride, and interleukin-6 were statistically lower in the penehyclidine hydrochloride group than in the control
group. Postoperatively, interleukin-10 did not differ between the penehyclidine hydrochloride and control
groups.
Conclusions: Penehyclidine hydrochloride preserves intestinal barrier function integrity, attenuates endotoxe-
mia, and inhibits systemic inflammatory response in patients undergoing cardiopulmonary bypass, possibly by
improving intestinal microcirculation and depressing stress response. (J Thorac Cardiovasc Surg 2013;146:179-85)P
MCardiopulmonary bypass (CPB) is an indispensable tech-
nique that temporarily takes over the function of the heart
and lungs for most cardiac operations, maintaining the cir-
culation of blood and the oxygen content of body. The non-
pulsatile flow during CPB results in splanchnic ischemia by
means of capillary closure and shunting. Intestinal ischemia
is paralleled by a disruption of the intestinal mucosal barrier
and an increase in intestinal wall permeability, which
causes translocation of luminal bacteria and the endotoxins
to pass into circulation.1-4 In addition, hypothermia
associated with CPB has been thought to increase the
production of endogenous endotoxins, probably because
of intestinal ischemia, decreasing intestinal motility, lower
enzyme activity, and impaired function of Kupffer cells.5e Department of Anesthesiology, General Hospital of Shenyang Commend,
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The Journal of Thoracic and CaThe endotoxemia after CPB adversely affects postoperative
recovery in patients with an associated mortality of 12%
to 67%.6
Classic anticholinergics, such as tropane alkaloids, dom-
inantly block acetylcholine receptors and exhibit a wide
range of biological activities, including antioxidation and
cytoprotective activity. However, these drugs exhibit classic
antimuscarinic side effects, including dry mouth and accel-
erated heart rates. A new anticholinergic drug, penehycli-
dine hydrochloride (PHC), was developed by the Institute
of Pharmacology and Toxicology, Academy of Military
Medical Sciences, to minimize the side effects harmful
to the cardiovascular system.7 Because PHC selectively
blocks M1, M3, and N receptors, there are few M2 recep-
tor–associated side effects, including dry mouth and accel-
erated heart rates.7 PHC has both antimuscarinic and
antinicotinic activities and retains potent central and periph-
eral anticholinergic activities.8 PHC is commonly used in
the clinic as an antagonist of organic phosphorus poisoning,
asthma, and chronic obstructive pulmonary diseases.9,10
More significant, clinical and experiment studies indicate
that PHC is beneficial in treating septic shock, acute lung
injury, and CPB-associated liver damage.11-15
On the basis of the potential role of PHC as an antioxi-
dant and a cell membrane stabilizer, we postulated thatrdiovascular Surgery c Volume 146, Number 1 179
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
I-FABP ¼ intestinal fatty acid binding protein
IL ¼ interleukin
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PHC ¼ penehyclidine hydrochloride
SIRS ¼ systemic inflammatory response
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TNF-a ¼ tumor necrosis factor-alpha
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MPHC therapy might be beneficial for the maintenance of
intestinal barrier integrity and subsequent attenuation of
endotoxemia and systemic inflammatory response syn-
drome (SIRS). Zhang and colleagues16 demonstrated that
PHC post-conditioning reduces small-intestine permeabil-
ity after limb ischemia–reperfusion by inhibiting oxygen
free radicals and inflammatory cytokines for organ dam-
age. More important, our previous research indicated that
PCH improves damage resulting from intestinal ischemia,
inhibits bacteria translocation, attenuates the release of en-
dotoxins, and further preserves the structure and function
of intestinal mucosa in a rat model of CPB.17 The purpose
of this study was to investigate whether PHC is effective in
preserving the intestinal barrier function and attenuating
the endotoxemia and SIRS in patients undergoing CPB.
In this study, blood glucose, lactic acid, intestinal fatty
acid binding protein (I-FABP), D-lactate, serum endotoxin
(lipopolysaccharide [LPS]), interleukin (IL)-6, and IL-10
levels were examined in serum. The dosage of PHC
administration, ranging from 0.03 to 0.45 mg/kg, has
been proved to be effective and curative in both animal
study and clinical investigation.11-17 In the study, the
dose of 0.05 mg/kg was administered to minimize the
side effects on patients.
PATIENTS AND METHODS
Patients
Forty patients undergoing cardiac valve replacement were followed pro-
spectively from September 2009 to April 2012. This study was approved by
the Institutional Committee on Human Research in the General Hospital of
ShenyangMilitary Region, and all patients provided informed consent. Ex-
clusion criteria were as follows: severe anemia, liver and renal insuffi-
ciency, any history or signs of endocrine or infectious disease, active or
history of nervous or mental disorders, disorders involving the intestines,
or disturbances in blood coagulation. All patients had an ejection fraction
greater than 50% before cardiac surgery. Eighteen patients underwent mi-
tral replacement, 12 patients underwent aortic replacement, and 10 patients
underwent combined mitral and aortic replacement. Bioprosthesis and me-
chanical valve implantation were performed in 14 and 26 subjects, respec-
tively. The patients were randomly divided into 2 groups: those who
received the injection of PHC (0.05 mg/kg, Lisite Pharmacology Co,
Chengdu, China, No. 080301) through the internal jugular vein 10 minutes
before the onset of CPB and those who received the same volume of saline
as a control.180 The Journal of Thoracic and Cardiovascular SurgAnesthesia
The patients fasted for at least 8 hours and received a glycerin enema
before the cardiac procedure. The radial artery was cannulated, and blood
pressure, heart rate, oxygen saturation, and electrocardiograph were
measured using a Datex-Ohmeda S/5 Anesthesia Monitor (GE Healthcare,
Helsinki, Finland). General anesthesia was induced with fentanyl 0.8 mg/kg,
etomidate 0.2 mg/kg, pipecuronium 0.1 mg/kg, and midazolam 0.1 mg/kg.
Maintenance of anesthesia was performed with infusion of fentanyl
5 to 10 mg/kg/h, boluses of midazolam 0.1 mg/kg and pipecuronium 0.1
mg/kg, and 0.6% to 0.8% end-tidal isoflurane. All patients were ventilated
with an oxygen–air mixture equal to an inspired oxygen fraction of 0.7 to
maintain an end-tidal carbon dioxide tension of 35 to 45 mmHg. After oral
tracheal intubation, a 3-lumen central venous catheter (Arrow, Reading, Pa)
was inserted into the right internal jugular vein.
Cardiopulmonary Bypass Technique
After performing amedian sternotomy, all patientsweregiven 300 to 400
U/kg heparin. The ascending aorta was cannulated, and venous cannulation
was usually accomplished by direct superior vena caval and inferior vena
caval cannulation. An extracorporeal circuit was used in all patients, which
comprised a JostraHL-20 heart-lungmachine (Jostra USA,Austin, Tex) for
nonpulsatile flow and a hollow-fiber membrane oxygenator with an integral
heat exchanger (Medtronic Cardiopulmonary, Anaheim, Calif) for gas ex-
change. The pump priming solution consisted of 1500 mL Ringer’s lactate
solution and 100 g of albumin. Activated clotting timesweremaintained for
at least 480 seconds, and hematocrit levels were kept at 25% to 30%. All
valvular replacements were performed under moderate hypothermia with
a nasopharyngeal temperature of 32C to 35C. A cold crystalloid cardio-
plegic solution was used. During CPB, the pump flow rate was 2.2 to 2.6
L/m2/min and the perfusion pressure was 50 to 80 mm Hg. On discontinu-
ation of the CPB, heparin was neutralized with protamine sulfate. Postoper-
atively, the patients were admitted to the intensive care unit (ICU). The
patients were extubated as soon as clinically indicated.
Clinical Indexes
At the time of hospital admission, demographics and medical diagnoses
were recorded. The durations of anesthesia, surgery, aorta crossclamping,
and CPB were recorded. At the time of ICU admission, the use of inotropes
and vasopressors was recorded. The durations of postoperative ventilation,
ICU, and hospital stays were recorded. The transfusion amount, occurrence
of severe complications, and deaths were also recorded.
Blood Samples
Blood sampling was performed in all patients at 6 time points: immedi-
ately after induction of general anesthesia (T0), 10 minutes after the release
of aorta clamping (T1), immediately after weaning from CPB (T2), 2 hours
postoperatively (T3), 6 hours postoperatively (T4), and 18 hours postoper-
atively (T5). All blood samples were obtained from the internal jugular vein
in an aseptic fashion. After blood sampling, a complete blood gas analysis
was performed using the Bayer Model 865 blood gas analyzer, and blood
glucose levels were determined with a glucose analyzer (ABL700, Radi-
ometer Medical, Copenhagen, Denmark). Plasma whole blood samples
(5 mL) were centrifuged for 10 minutes at 3500g, and the supernatants
were stored at70C until measurement. Serum IL-6 and IL-10 were mea-
sured by enzyme-linked immunosorbent assay kits (Wuhan Boster Biolog-
ical Technology, Ltd,Wuhan, China). Serum I-FABPwas determined using
a enzyme-linked immunosorbent assay kit (Beijing Sunbio Biological
Technology, Ltd, China). Serum D-lactate levels were measured using an
enzymatic spectrophotometric assay using a centrifugal analyzer at 30C
as described previously.18 Serum endotoxin levels were determined using
modified perchloric acid extraction. All data were normalized to remove
the influence of hemodilution according to the following formula: the
normalized data ¼ the measured data 3 [Hctpreoperative – Hctpostoperative].ery c July 2013
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All experimental data were reported as mean  standard deviation and
analyzed using SPSS for Windows 13.0 (SPSS Inc, Chicago, Ill). Student
t test was used for comparison among groups. Intergroup comparisons
were analyzed using repeated-measures analysis of variance.RESULTS
Patients
The patients’ clinical data and demographics are summa-
rized in Table 1. Demographic characteristics such as age,
gender, and weight did not differ between the groups. There
were no differences between groups in the durations of aorta
clamping, CPB, and surgery. There were no differences be-
tween the groups in the transfusion amount, duration of me-
chanical ventilation, or length of ICU or hospital stay. All
patients recovered uneventfully without having the occur-
rence of severe complications or death.Blood Glucose and Lactic Acid
Blood glucose and lactic acid levels from both patient
groups at the various time points are presented in
Figure 1. Blood glucose and lactate acid levels in both
groups were significantly increased after the onset of CPB
and peaked at 6 hours postoperatively (P< .05). There
were no marked differences in blood glucose or lactic
acid levels preoperatively between the 2 groups (P>.05).
Blood glucose levels at all time points after the onset of
CPB were lower in the PHC group than in the control group,
and these differences reached statistical differences at 10
minutes after the release of aorta clamping (P ¼ .031)
and at 2 hours postoperatively (P¼ .025). Lactic acid levels
at all time points after the onset of CPB were lower in the
PHC group than in the control group, and this differenceTABLE 1. Demographics and clinical data of patients in the two
groups
PHC group
(n ¼ 20)
Control group
(n ¼ 20)
P
value
Gender (M/F) 7/13 9/11
Age (y) 51.45  8.61 54.14  5.16 .082
Weight (kg) 58.57  7.43 58.86  6.57 .104
Mitral vale replacement (%) 10 (50%) 8 (40%) .078
Aortic valve replacement (%) 5 (25%) 7 (35%) .096
Combined valve
replacement (%)
5 (25%) 5 (25%) .156
Duration of aorta clamping
(min)
56.20  12.77 61.10  9.30 .095
Duration of CPB (min) 96.70  17.05 103.00  11.36 .087
Duration of surgery (min) 175.90  16.31 181.60  9.24 .074
Transfusion amount 675.00  85.00 650.00  90.00 .086
Duration of ventilation (h) 9.52  5.65 10.35  6.24 .075
Duration of ICU (d) 3.96  1.25 4.38  1.75 .096
Duration of hospital (d) 22.35  7.93 23.52  8.72 .085
PHC, Penehyclidine hydrochloride; CPB, cardiopulmonary bypass; ICU, intensive
care unit.
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Mwas statistically significant immediately after weaning
from CPB (P ¼ .019).
Intestinal Fatty Acid Binding Protein, D-Lactate, and
Lipopolysaccharide
Serum I-FABP, D-lactate, and LPS levels from both pa-
tient groups at the various time points are presented in
Figure 2. Serum I-FABP, D-lactate, and LPS levels in
both groups were significantly increased after the onset of
CPB (P<.05). I-FABP peaked at 6 hours postoperatively,
D-lactate peaked at 2 hours postoperatively, and LPS
peaked immediately after weaning from CPB. There were
no marked differences in serum I-FABP, D-lactate, and
LPS levels preoperatively between the 2 groups (P>.05).
Serum I-FABP, D-lactate, and LPS levels at all time
points after the onset of CPB were lower in the PHC group
than in the control group. These differences in serum
I-FABP were statistically significant 10 minutes after the
release of aorta clamping (P ¼ .015), at 2 hours postopera-
tively (P¼ .033), and at 6 hours postoperatively (P¼ .046).
These differences in D-lactate were statistically significant
immediately after weaning from CPB (P ¼ .039) and at 2
hours postoperatively (P ¼ .028). These differences in
LPS were statistically significant immediately after wean-
ing from CPB (P ¼ .036), 2 hours postoperatively
(P ¼ .029), and 6 hours postoperatively (P ¼ .034).
Interleukin-6 and 10
Serum IL-6 and IL-10 levels from both patient groups at
the various time points are presented in Figure 3. Serum
IL-6 and IL-10 levels in both groups were significantly in-
creased after the onset of CPB and peaked at 6 hours post-
operatively (P<.05). There were no marked differences in
IL-6 and IL-10 levels preoperatively between the 2 groups
(P>.05).
Serum IL-6 levels at all time points after the onset of CPB
were lower in the PHC group than in the control group, and
these differences were statistically significant at 2 hours
postoperatively (P ¼ .024) and 6 hours postoperatively
(P¼ .043). There were no differences in serum IL-10 levels
at all time points after the onset of CPB between the 2
groups (P>.05).
DISCUSSION
The intestine has been an organ of interest in the initiation
and perpetuation of the inflammatory response after sur-
gery.19 The intestines also act as a barrier to prevent micro-
organisms and toxins contained within the lumen from
spreading to distant tissues and organ. Impairment of the
intestinal barrier often occurs in CPB because of inherent
nonpulsatile flow and hypoxia, resulting in the increased
intestinal permeability and subsequent translocation of bac-
teria and endotoxins from gut.1-5 Bacteria translocation and
endotoxemia play a key role in the development of SIRSrdiovascular Surgery c Volume 146, Number 1 181
FIGURE 1. Blood glucose and lactic acid levels in both groups were significantly Increased after the onset of CPB and peaked at 6 hours postoperatively
(P<.05). Blood glucose levels were statistically lower in the PHC group than in the control group at 10minutes after the release of aorta clamping (P¼ .031)
and at 2 hours postoperatively (P ¼ .025). Lactic acid levels were statistically less in the PHC group than in the control group immediately after weaning
from CPB (P ¼ .019). PHC, Penehyclidine hydrochloride.
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Mand multiple organ failure. Thus, the protection of intestinal
barrier integrity is extremely critical for the attenuation of
endotoxemia and SIRS after CPB. Our previous study
demonstrated that PHC protected the structure and
function of the intestinal mucosa in a rat model of CPB.
The recent study focused on intestinal barrier injury,
endotoxemia, SIRS, and the therapeutic potential of PHC
in patients undergoing CPB.
CPB is a nonphysiologic intervention that leads to amajor
surge in counter-regulatory hormones, including adrenal
cortex hormone, glucagon, and catecholamines, which are
accompanied by an insulin-resistant state with subsequent
stimulation of glucose and hyperglycemia.20 The accumula-
tion of lactic acid is the direct result of oxygen deprivation
and anaerobic metabolism. The nonpulsatile perfusion dur-
ing CPB causes splanchnic ischemia by inducing capillary
closure and shunting.21 Conversely, a continuous-flow left
ventricular assist device is able to diminish vascular imped-
ance, increase vascular compliance, and improve splanch-
nic perfusion.22,23 During periods of the ischemia and
hypovolemia, the intestine vasoconstricts and shunts
blood toward more vital organs, such as the heart and
brain.24 The intestine is one of the most susceptible organs
to hypoperfusion during conditions of stress.24 Thus, blood182 The Journal of Thoracic and Cardiovascular Surgglucose and lactic acid concentrations are the useful
markers to assess stress response and intestinal ischemia
after CPB. In this study, the levels of blood glucose and lac-
tic acids were significantly increased after the onset of CPB.
These demonstrated that CPB resulted in stress hyperglyce-
mia and splanchnic ischemia. More important, our study
showed that PHC therapy significantly inhibited the eleva-
tion of blood glucose and lactic acids, illustrating that
PHC attenuates CPB-associated stress responses and
improves splanchnic ischemia.
I-FABP is a 14-kDa cytosolic protein uniquely located in
mature small-intestinal enterocytes. It is involved in the
uptake and transport of fatty acids from the small-bowel lu-
men. I-FABP normally is almost undetectable in serum.
I-FABP is released into the peripheral circulation early after
intestinal ischemia and has been shown to be a sensitive and
specific biochemical marker to facilitate the early detection
of intestinal ischemia.25 I-FABP is extremely stable at room
temperature and can maintain the total activity of 95% for
24 hours, which facilitate the detection of its serum level.25
D-lactate is an indigenous product produced by some gut
bacteria. Serum D-lactate in mammals normally is low.
During ischemic events, the mucosa is injured and intestinal
permeability is increased, leading to the translocation of gutery c July 2013
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FIGURE 2. I-FABP, D-lactate, and LPS levels in both groups were significantly increased after the onset of CPB (P<.05). I-FABP, D-lactate, and LPS
levels peaked at 6 hours postoperatively, 2 hours postoperatively, and immediately after weaning from CPB, respectively. I-FABP levels were statistically
lower in the PHC group than in the control group at 10 minutes after the release of the aortic clamp (P¼ .015), at 2 hours postoperatively (P¼ .033), and at
6 hours postoperatively (P¼ .046). D-lactate levels were statistically less in the PHC group than in the control group immediately after weaning from CPB
(P¼ .039) and at 2 hours postoperatively (P¼ .028). LPS levels were statistically less in the PHC group than in the control group immediately after weaning
from CPB (P ¼ .036), 2 hours postoperatively (P ¼ .029), and 6 hours postoperatively (P ¼ .034). I-FABP, Intestinal fatty acid binding protein; LPS,
lipopolysaccharide; PHC, penehyclidine hydrochloride.
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Mbacteria and its metabolic products, including D-lactate,
into circulation. As early as 2 hours postoperatively, ele-
vated plasma levels of D-lactate were measured in subjects
with histologically proven intestinal ischemia.26 The trans-
location of gut bacteria further results in the elevated con-
centration of serum endotoxin. Thus, plasma D-lactate
and serum endotoxin levels have been shown to be a useful
marker used to monitor an increase in intestinal permeabil-
ity, bacterial translocation, and endotoxemia after CPB in
early stages.27 In this study, serum I-FABP, D-lactate, and
endotoxin were substantially increased after the onset of
CPB. This demonstrated that CPB impaired intestinal bar-
rier function integrity and increased intestinal permeability
with resultant bacterial translocation and endotoxemia.
More significant, our study indicated that PHC therapy in-
hibits the elevation of I-FABP, D-lactate, and serum endo-
toxin, illustrating that PHC is beneficial in preserving the
integrity of intestinal barrier function and depressing theThe Journal of Thoracic and Catranslocation of gut bacteria and endotoxin. It is possible
that PHC protects intestinal barrier function by stabilizing
the cell membrane and enhancing the tolerance of entero-
cytes to hypoxia.16,17
Inflammatory cytokine responses after CPB are physio-
logic and associated with a host systemic inflammatory re-
sponse to exogenous stimulation. IL-6 functions as
a proinflammatory cytokine and is one of the most impor-
tant mediators of fever and the acute phase systemic re-
sponse.28 The inflammatory response can lead to
a compensatory anti-inflammatory reaction. IL-10 is an
anti-inflammatory cytokine and is capable of inhibiting syn-
thesis of proinflammatory cytokines, such as IL-6 and tu-
mor necrosis factor-alpha (TNF-a). The severity of the
systemic inflammatory response is prominently influenced
by the balance between proinflammatory and anti-
inflammatory cytokines. In this study, we found that serum
levels of IL-6 and IL-10 were significantly increased afterrdiovascular Surgery c Volume 146, Number 1 183
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FIGURE 3. IL-6 and IL-10 levels in both groups were significantly increased after the onset of CPB and peaked at 6 hours postoperatively (P<.05). IL-6
levels were statistically lower in the PHC group than in the control group at 2 hours postoperatively (P ¼ .024) and at 6 hours postoperatively (P ¼ .043).
There were no differences in IL-10 levels postoperatively between the 2 groups (P>.05). IL, Interleukin; PHC, penehyclidine hydrochloride.
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Mthe onset of CPB. This indicated that CPB initiated a proin-
flammatory and compensatory anti-inflammatory response.
More significant, we also found that PHC therapy inhibits
the elevation of IL-6 and did not change serum IL-10, illus-
trating that PHC attenuates the release of proinflammatory
mediators and maintained the anti-inflammatory response.
PHC is a novel therapeutic agent that exhibits protective
effects on intestinal barrier function in animal models of
CPB and limb ischemia–reperfusion.16,17 In addition,
previous investigations have reported that PHC therapy
has curative effects after liver injury, acute lung injury,
and septic shock. Zhan and colleagues11 demonstrated
that PHC was effective in treating lung and liver damage
during sepsis, and its mechanism of action was probably
mediated by inhibition of inflammatory factor production
(TNF-a) and suppression of lipid peroxidation. Li et al12
found that PHC substantially attenuates LPS-induced acute
lung injury through inhibition of nuclear factor-kb activa-
tion, TNF-a and IL-1 production, and pulmonary neutrophil
accumulation. Zhan and colleagues13 found that PHC ame-
liorates sepsis-induced acute lung injury through the down-
regulation of IL-6 production. Li et al14 demonstrated that
PHC prevents the development of acute lung injury by
downregulating serum IL-1, IL-8, and TNF-a expression.
Cai et al15 found that PHC was capable of lowering the
serum levels of liver enzymes, which led to an attenuation
of damage to liver tissue in a rat model of CPB.184 The Journal of Thoracic and Cardiovascular SurgStudy Limitations
The study has 2 major limitations. First, serum indicators
were selected to determine the effect of PHC on intestinal
barrier function and systemic inflammatory response.
Because of the limited availability of tissue specimen, no
tissue examination was performed to further confirm the
conclusion. Second, although PCH has been proved to be
effective on protecting intestinal barrier function, it does
not selectively target the intestine and might exert side ef-
fects on several organs. Further investigations are required
to understand its effects on a single organ.
CONCLUSIONS
PCH may preserve intestinal barrier function integrity,
attenuate endotoxemia, and inhibit the systemic inflamma-
tory response in patients undergoing CPB. It is likely that
PCH mediates these responses by improving intestinal
microcirculation and depressing stress response.
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